GAITHERSBURG, Md.--(BW HealthWire)--May 8, 2001--Gene Logic Inc. (Nasdaq:GLGC - news), an integrated biological information and bioinformatics company, announced today that AstraZeneca Pharmaceuticals (NYSE:AZN; FTSE:AZN; Stockholm:AZN) has subscribed to the full GeneExpress®Suite of databases, including the BioExpress(TM) Module and the ToxExpress(TM) Module, for use in AstraZeneca's drug discovery and development programs.
Financial terms of the multi-year subscription agreement were not disclosed.
``As AstraZeneca Discovery continues to expand its genetic and genomic analysis capabilities, we are delighted to add Gene Logic's GeneExpress® database products to our own extensive portfolio of gene expression information,'' commented John Stageman, Vice President of Enabling Science and Technology for AstraZeneca. ``Access to this information will allow our scientists to view the results of their own expression experiments from a much broader perspective and we look forward to working alongside Gene Logic in building and mining this rich information source derived from diverse tissues and disease states. The GeneExpress® Suite will integrate well into our sophisticated internal bioinformatics platform which links public, proprietary and project data together and which is provided on the desktops of all our bioscientists worldwide.''
The BioExpress(TM) Module consists of gene expression and associated clinical information from a broad range of normal and diseased human tissues, tissues from model animal systems and human and animal cell lines, for use in target identification and target validation studies.
The ToxExpress(TM) Module is a reference library of toxicity markers derived from examination of known toxic compounds in rodent model systems and across human and rat primary cell lines. The ToxExpress(TM) Module is a tool for prioritizing candidate compounds currently in research.
The multi-year subscription agreement provides for broad deployment of both segments of the GeneExpress® Suite, as well as its related GeneExpress® 2000 data mining, analysis and visualization software platform across AstraZeneca's global research and development infrastructure.
``We are delighted to announce this subscription to the full GeneExpress® Suite by AstraZeneca, one of the leading global pharmaceutical companies,'' stated David S. Murray, Senior Vice President for Marketing and Sales for Gene Logic. ``As part of their subscription, AstraZeneca researchers will gain access to the BioExpress(TM) Module, with its growing catalogue of gene expression data on the genetic sources of human health and disease, and to the ToxExpress(TM) Module, which contains some of the most comprehensive information on toxicology available today, an increasingly important element for the industry. We look forward to the GeneExpress® Suite becoming an integral component in AstraZeneca's drug development research through their access to this rich source of unique genomic information and powerful bioinformatics.''... |
